07:00 , Aug 12, 2013 |  BC Week In Review  |  Clinical News

ISIS-CRPRx: Development discontinued

Isis discontinued development of ISIS-CRPRx to treat RA after data from a double-blind, Canadian and Russian Phase II trial in 51 RA patients with chronically elevated CRP levels showed that ISIS-CRPRx did not significantly improve...
07:00 , Aug 12, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) was down $1.43 to $18.43 last week after disclosing that FDA denied breakthrough therapy designation for AP26113 for anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). Ariad said...
00:00 , Aug 6, 2013 |  BC Extra  |  Clinical News

Isis drops ISIS-CRPRx for RA, continues for AF

Isis Pharmaceuticals Inc. (NASDAQ:ISIS) discontinued development of ISIS-CRPRx to treat rheumatoid arthritis after data from a Phase II trial showed the compound did not significantly improve signs and symptoms of RA as measured by ACR20...
08:00 , Mar 4, 2013 |  BC Week In Review  |  Clinical News

ISIS-CRPRx: Phase II started

Isis began the double-blind, placebo-controlled, crossover, U.K. Phase II ASET trial to evaluate multiple doses of ISIS-CRPRx in about 20 patients with AF who have pacemakers. The product is also in Phase II testing for...
07:00 , Oct 8, 2012 |  BC Week In Review  |  Clinical News

MGN1601: Updated Phase I/II data

Updated data from 10 evaluable patients who completed 12 weeks of treatment in the open-label, German Phase I/II ASET trial showed that MGN1601 led to median overall survival (OS) of >16 months and produced 7...
07:00 , Apr 16, 2012 |  BC Week In Review  |  Clinical News

MGN1601: Additional Phase I/II data

Data from 10 evaluable patients who completed 12 weeks of treatment in the open-label, German Phase I/II ASET trial showed that MGN1601 led to an average survival time of >10 months with 1 partial response...
07:00 , Sep 5, 2011 |  BC Week In Review  |  Clinical News

MGN1601: Preliminary Phase I/II data

Preliminary data from an undisclosed number of patients in the open-label, German Phase I/II ASET trial showed that MGN1601 was well tolerated for 12 weeks, with no serious adverse events. Additionally, MGN1601 halted the progression...
08:00 , Dec 20, 2010 |  BC Week In Review  |  Clinical News

MGN1601: Phase I/II started

Mologen began the open-label, German Phase I/II ASET trial to evaluate MGN1601 in 24 patients for 12 weeks. MGN1601 has Orphan Drug designation in the EU for the indication. Mologen AG (Xetra:MGN), Berlin, Germany  ...